Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 243 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Karagiannis, Asterios [Clear All Filters]
Focal nodular hyperplasia of the liver in a patient with primary aldosteronism..
J Gastroenterol Hepatol. 19(4), 480-1.
(2004). Lack of an association between angiotensin converting enzyme gene polymorphism and peripheral arterial occlusive disease..
Vasc Med. 9(3), 189-92.
(2004). Lack of an association between angiotensin-converting enzyme gene insertion/deletion polymorphism and ischaemic stroke..
Eur Neurol. 51(3), 148-52.
(2004). Paralysis as first manifestation of primary aldosteronism..
Nephrol Dial Transplant. 19(9), 2418-9.
(2004). Plasma B-type natriuretic peptide is related to left ventricular mass in hypertensive patients..
Eur Heart J. 25(21), 1967.
(2004).
(2004). Acute renal failure due to tumor lysis syndrome in a patient with non-Hodgkin's lymphoma..
Ann Hematol. 84(5), 343-6.
(2005). Gonadal dysfunction in systemic diseases..
Eur J Endocrinol. 152(4), 501-13.
(2005). Targeting vascular risk in patients with metabolic syndrome but without diabetes..
Metabolism. 54(8), 1065-74.
(2005).
(2005). Dry cough as first manifestation of giant-cell arteritis..
J Am Geriatr Soc. 54(12), 1957-8.
(2006). Dyslipidaemia, hypercoagulability and the metabolic syndrome..
Curr Vasc Pharmacol. 4(3), 175-83.
(2006). Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study..
Curr Med Res Opin. 22(5), 873-83.
(2006). Should atenolol still be recommended as first-line therapy for primary hypertension?.
Hellenic J Cardiol. 47(5), 298-307.
(2006). Vascular endothelial growth factor and nitric oxide serum levels in arterial hypertension..
Clin Exp Hypertens. 28(7), 603-9.
(2006). Is angioedema a class adverse effect of the angiotensin-converting enzyme inhibitors?.
Ann Allergy Asthma Immunol. 98(5), 502.
(2007). Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?.
Expert Opin Pharmacother. 8(5), 529-35.
(2007). Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, CHD, stroke, and peripheral arterial disease in a Mediterranean cohort..
Angiology. 58(6), 689-97.
(2007). Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?.
Curr Pharm Des. 13(2), 229-39.
(2007). Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients..
Lipids. 42(11), 999-1009.
(2007). Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?.
Expert Opin Pharmacother. 8(14), 2267-77.
(2007). Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with CHD and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study..
Nephrol Dial Transplant. 22(1), 118-27.
(2007). Endothelial function, arterial stiffness and lipid lowering drugs..
Expert Opin Ther Targets. 11(9), 1143-60.
(2007). Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism..
Nephrol Dial Transplant. 22(1), 293.
(2007). Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels..
Curr Drug Targets. 8(3), 483-8.
(2007).